Expected population impacts of discontinued prostate-specific antigen screening.

ABSTRACT:

Background

Prostate-specific antigen (PSA) screening for prostate cancer has high risks of overdiagnosis, particularly among older men, and reports from screening trials indicate that it saves few lives after 11 to 13 years of follow-up. New clinical guidelines recommend against PSA screening for all men or for men aged >70 years, but, to the authors' knowledge, the expected population effects of these guidelines have not been studied to date.

Methods

Two models of prostate cancer natural history and diagnosis were previously developed using reconstructed PSA screening patterns and prostate cancer incidence in the United States. Assuming a survival benefit of PSA screening consistent with the screening trials, the authors used the models to predict incidence and mortality ra

SUBMITTER: Gulati R 

PROVIDER: S-EPMC4221407 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature